Company profile
Rafarma Pharmaceuticals, Inc.
OTC: RAFA · Healthcare · Drug Manufacturers - Specialty & Generic
#644 of 1,422 Healthcare companies by revenue44th-percentile growth
EA Score
71BFH 83DQ —GM 41SS 61
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, return on assets · ↓ 3-yr revenue growth, market scale
Methodology →Revenue TTM
$9.2M
Rev growth YoY (TTM)
+1.6%
Net income (FY)
$349.0k
Employees
700
as of 2026-08-25
Market cap
$3.2M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.2M$9.2M2025
Net income$349.0k$349.0k2025
Operating income$489.0k$489.0k2025
Total assets$12.0M$12.0M2025
Liabilities$1.5M$1.5M2025
Equity$10.5M$10.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rafarma Pharmaceuticals, Inc.’s revenue?
Rafarma Pharmaceuticals, Inc. booked $9.2M in FY2025 revenue, growing 1.1% year over year — about the middle of the pack among Healthcare companies we track, at a 3.8% net margin.
Peers · Healthcare
Yulong Eco-Materials Limited——ThermoGenesis Holdings, Inc.——Curis, Inc.53DInternational Stem Cell Corporation57CNeuroOne Medical Technologies Corporation55CHempfusion Wellness Inc.——Neighbors
Salt Lake →Key facts
CEOSergey Brusnitsin
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSandy, UT
ExchangeOTC: RAFA
Employees700
IPO date2012-12-11
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.